Marc C Chamberlain1. 1. Department of Neurology and Neurosurgical Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109-1023, USA. chambemc@u.washington.edu
Abstract
BACKGROUND: Based on limited literature, an at risk group of patients for development of neoplastic meningitis (NM) are those with resected cerebellar parenchymal metastases. OBJECTIVE: Characterize the incidence of NM in patients with cerebellar metastases treated with either surgical resection or radiotherapy. PATIENTS AND METHODS: A retrospective study to determine outcome and in particular the occurrence of NM in 30 patients with resected cerebellar metastases (Group 1) and in 50 patients with cerebellar metastases treated with radiotherapy only (Group 2). Additionally, 10 patients with coincident cerebellar metastases and NM were identified (Group 3) and compared with these groups. RESULTS: Median survival in Group 1 was 8 months (range 4-24 months). A single patient (1/30; 3%) in this cohort developed NM that was not treated. Median survival in Group 2 was 4 months (range 1.5-18 months). Two patients (2%) in Group 2 developed NM, in neither was the NM treated. Group 3 had a median survival of 3 months (range 1-6 months). No patient in Group 3 had a history of prior posterior fossa surgery. CONCLUSIONS: The incidence of NM following resection of cerebellar metastases (3%: Group 1) was no greater than that seen following treatment of cerebellar metastases with radiotherapy only (2%; Group 2). In addition, in a large data base of patients with NM (40% with parenchymal metastases), cerebellar metastases occurred at a proportion (10%; Group 3) expected based on proportional brain volume and cerebral blood flow.
BACKGROUND: Based on limited literature, an at risk group of patients for development of neoplastic meningitis (NM) are those with resected cerebellar parenchymal metastases. OBJECTIVE: Characterize the incidence of NM in patients with cerebellar metastases treated with either surgical resection or radiotherapy. PATIENTS AND METHODS: A retrospective study to determine outcome and in particular the occurrence of NM in 30 patients with resected cerebellar metastases (Group 1) and in 50 patients with cerebellar metastases treated with radiotherapy only (Group 2). Additionally, 10 patients with coincident cerebellar metastases and NM were identified (Group 3) and compared with these groups. RESULTS: Median survival in Group 1 was 8 months (range 4-24 months). A single patient (1/30; 3%) in this cohort developed NM that was not treated. Median survival in Group 2 was 4 months (range 1.5-18 months). Two patients (2%) in Group 2 developed NM, in neither was the NM treated. Group 3 had a median survival of 3 months (range 1-6 months). No patient in Group 3 had a history of prior posterior fossa surgery. CONCLUSIONS: The incidence of NM following resection of cerebellar metastases (3%: Group 1) was no greater than that seen following treatment of cerebellar metastases with radiotherapy only (2%; Group 2). In addition, in a large data base of patients with NM (40% with parenchymal metastases), cerebellar metastases occurred at a proportion (10%; Group 3) expected based on proportional brain volume and cerebral blood flow.
Authors: Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321